EP3727353A4 - Surfactant formulations for inhalation - Google Patents

Surfactant formulations for inhalation Download PDF

Info

Publication number
EP3727353A4
EP3727353A4 EP18890080.7A EP18890080A EP3727353A4 EP 3727353 A4 EP3727353 A4 EP 3727353A4 EP 18890080 A EP18890080 A EP 18890080A EP 3727353 A4 EP3727353 A4 EP 3727353A4
Authority
EP
European Patent Office
Prior art keywords
inhalation
surfactant formulations
formulations
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18890080.7A
Other languages
German (de)
French (fr)
Other versions
EP3727353A1 (en
Inventor
Michael M. Lipp
Holly CHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Civitas Therapeutics Inc
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of EP3727353A1 publication Critical patent/EP3727353A1/en
Publication of EP3727353A4 publication Critical patent/EP3727353A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP18890080.7A 2017-12-21 2018-12-19 Surfactant formulations for inhalation Pending EP3727353A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609277P 2017-12-21 2017-12-21
PCT/US2018/066435 WO2019126289A1 (en) 2017-12-21 2018-12-19 Surfactant formulations for inhalation

Publications (2)

Publication Number Publication Date
EP3727353A1 EP3727353A1 (en) 2020-10-28
EP3727353A4 true EP3727353A4 (en) 2021-10-13

Family

ID=66995083

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18890080.7A Pending EP3727353A4 (en) 2017-12-21 2018-12-19 Surfactant formulations for inhalation

Country Status (7)

Country Link
US (1) US20210386664A1 (en)
EP (1) EP3727353A4 (en)
JP (2) JP7335263B2 (en)
AU (1) AU2018392461A1 (en)
CA (1) CA3085944A1 (en)
MX (1) MX2020006634A (en)
WO (1) WO2019126289A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085943A1 (en) * 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035882A1 (en) * 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2006055532A2 (en) * 2004-11-15 2006-05-26 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
WO2008011559A2 (en) * 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
WO2008036293A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
CN102049040A (en) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 Artificial surface-active substance mixed liquid as well as preparation and application thereof
WO2013149013A1 (en) * 2012-03-28 2013-10-03 Discovery Laboratories, Inc. Lyophilization of synthetic liposomal pulmonary surfactant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315983B1 (en) 1996-01-24 2001-11-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for the production of powdered pulmonary surfactant preparations
JP2003507410A (en) 1999-08-25 2003-02-25 アドバンスト インハレーション リサーチ，インコーポレイテッド Controlled release from dry powder formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US20030091509A1 (en) * 2000-02-11 2003-05-15 Haefner Dietrich Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
DK1455755T3 (en) * 2001-11-20 2013-07-15 Civitas Therapeutics Inc Improved particle composition for delivery in lung
AU2003280102B2 (en) * 2002-06-28 2007-01-25 Alkermes, Inc. Inhalable epinephrine
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
EP3474832A1 (en) * 2016-06-24 2019-05-01 Civitas Therapeutics, Inc. Surfactant formulations for inhalation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035882A1 (en) * 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2006055532A2 (en) * 2004-11-15 2006-05-26 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
WO2008011559A2 (en) * 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
WO2008036293A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
CN102049040A (en) * 2009-10-30 2011-05-11 北京隆旗生物科技有限公司 Artificial surface-active substance mixed liquid as well as preparation and application thereof
WO2013149013A1 (en) * 2012-03-28 2013-10-03 Discovery Laboratories, Inc. Lyophilization of synthetic liposomal pulmonary surfactant

Also Published As

Publication number Publication date
WO2019126289A1 (en) 2019-06-27
JP7335263B2 (en) 2023-08-29
EP3727353A1 (en) 2020-10-28
AU2018392461A1 (en) 2020-07-02
US20210386664A1 (en) 2021-12-16
MX2020006634A (en) 2021-01-15
JP2023144081A (en) 2023-10-06
JP2021508734A (en) 2021-03-11
CA3085944A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
EP3582755A4 (en) Formulations
IL273541A (en) Formulations
EP3638215A4 (en) Rna formulations
EP3270960A4 (en) Vector formulations
EP3346997A4 (en) Bioorthogonal compositions
EP3302437B8 (en) Stable cannabinoid formulations
IL269630A (en) Niraparib formulations
EP3148589A4 (en) Stable cannabinoid formulations
EP3509581A4 (en) Formulations of (r
IL269621A (en) Niraparib formulations
IL273282A (en) Niraparib formulations
EP3462885A4 (en) Stable cannabinoid formulations
EP3600257B8 (en) Alkaline phosphatase formulations
EP3498811A4 (en) Surfactant composition
EP3484288A4 (en) Pesticidal compositions
EP3580321A4 (en) Cleaning formulations
EP3508532A4 (en) Surfactant composition
EP3508269A4 (en) Surfactant composition
EP3682016A4 (en) Formulations for compound delivery
EP3600279A4 (en) 1-amino-1-cyclopropanecaboxylic acid formulations
EP3429581A4 (en) Enalapril formulations
ZA201900337B (en) Surfactant formulations for inhalation
EP3373928A4 (en) Novel formulations
EP3454658A4 (en) Glyphosate formulations containing amidoalkylamine surfactants
EP3727418A4 (en) Surfactant formulations for inhalation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038560

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210914

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/47 20060101ALI20210908BHEP

Ipc: A61K 9/00 20060101ALI20210908BHEP

Ipc: C07K 14/785 20060101ALI20210908BHEP

Ipc: A61P 11/16 20060101ALI20210908BHEP

Ipc: A61K 9/16 20060101ALI20210908BHEP

Ipc: A61K 9/72 20060101AFI20210908BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CIVITAS THERAPEUTICS, INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230411